Status:

COMPLETED

Revised Algorithm for Next Generation DeVilbiss Healthcare AutoAdjust Continuous Positive Airway Pressure (CPAP)

Lead Sponsor:

DeVilbiss Healthcare LLC

Conditions:

Obstructive Sleep Apnea

Eligibility:

All Genders

21-75 years

Phase:

NA

Brief Summary

The purpose of this protocol is to improve the current FDA-approved continuous positive pressure auto-titration algorithm, including treatment precision, residual disease detection characteristics and...

Eligibility Criteria

Inclusion

  • Apnea hypopnea index ≥ 15 / hour of sleep on the diagnostic polysomnogram, or diagnostic component of a split night polysomnogram
  • Sleep efficiency reported on CPAP titration night PSG should be \> 78%
  • Diagnosis of moderate to severe obstructive sleep apnea (AHI ≥15) or central/complex sleep apnea
  • On stable CPAP or APAP \[Automatic Positive Airway Pressure\] therapy, with compliant use averaging 4 or more hours nightly
  • Age 21-75 years
  • Predominately central sleep apnea for up to 10 subjects only
  • Willingness to give written informed consent and ability to adhere to visit schedule

Exclusion

  • Diagnosis of mild sleep apnea
  • CPAP naïve patients
  • Co-morbid conditions which render participation to be at risk. These may include patients with congestive heart failure, COPD \[Chronic Obstructive Pulmonary Disease\] or psychiatric illness
  • Allergies to mask materials
  • Evidence of another primary sleep disorder
  • Evidence of arousing periodic limb movements during titration
  • Contraindications as listed on product labeling
  • Pregnant
  • Currently diagnosed with depression if symptomatic
  • Deemed medically unsuitable by investigator
  • Evidence of any type of infection or treatment of an infectious condition during the period of research participation
  • Have a bi-level requirement, or prescribed a bi-level therapy device
  • CPAP pressure \>15cmH2O
  • Subjects with tracheotomy
  • Uncontrolled hypertension
  • Require supplemental oxygen
  • Stimulants, major tranquillizers or antipsychotics
  • Restless Leg Syndrome or Periodic Leg Movement Index of \> 5 per hour

Key Trial Info

Start Date :

January 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2014

Estimated Enrollment :

33 Patients enrolled

Trial Details

Trial ID

NCT01797705

Start Date

January 1 2013

End Date

May 1 2014

Last Update

May 29 2015

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

NeuroCare, Inc.

Newton, Massachusetts, United States, 02459